RxSight, Inc. (NASDAQ: RXST) reported Q2 EPS of $0.00, $0.22 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $34.9 million versus the consensus estimate of $32.33 million.

GUIDANCE:

RxSight, Inc. sees FY2024 revenue of $139-140 million, versus the consensus of $135.2 million.

Operating expenses in the range of $135.0 million to $136.0 million, representing an implied increase of 30% to 31% compared to 2023, up from prior guidance of $126.0 million to $130.0 million and including higher non-cash stock-based compensation expense guidance in the range of $29.0 million to $30.0 million, up from prior guidance of $22.0 million to $25 million.

Additionally, gross margin full-year 2024 guidance remained unchanged in the range of 68% to 70%.

For earnings history and earnings-related data on RxSight, Inc. (RXST) click here.